EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
EQS-News: SARTORIUS AG
/ Key word(s): Alliance
Göttingen, Germany | May 13, 2024
Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing. Selected as a preferred supplier, Sartorius will contribute its engineering and manufacturing expertise to commercialize ICB platforms based on prototypes developed by Sanofi. In return, Sanofi will grant Sartorius exclusive access to its know-how and patents related to the ICB platform. Sartorius is committing to the rapid development of hardware, consumables and process automation for diverse applications and volumes from development to commercial scale. As part of the collaboration and license agreement, Sartorius will exclusively commercialize the ICB platform offering to customers worldwide. “Technological innovation is crucial for biopharmaceutical companies to significantly reduce the cost of drug manufacturing - while improving the environmental footprint of their operations – and ultimately getting life-saving drugs to patients faster. As the biologics landscape becomes more diverse, teaming up with Sanofi is an excellent basis for developing a unique modular platform that combines flexibility with the advantages of intensified bioprocessing. This collaboration will help Sartorius to further expand its position as a leading company in the field of integrated and continuous bioprocessing,” said Jan Schäfer, Head of Separation Systems at Sartorius. Integrated continuous biomanufacturing is an advanced approach to the production of biopharmaceuticals. The concept aims to maximize efficiency by enabling uninterrupted and steady materials flow, as opposed to traditional batch methods, and by integrating multiple unit operations into a lean process setup. ICB reduces the overall process footprint, leading to lower raw material and energy consumption, higher productivity, and less waste. Sartorius offers a wide array of applications for process intensification in both upstream and downstream, ranging from high-throughput tools for process development to scalable, flexible manufacturing solutions. A profile of Sartorius Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe. Visit our newsroom and follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 (0)551.308.4067 Leona.malorny@sartorius.com Additional features: File: 20240513_SAG_Media Release_Sartorius collaborates with Sanofi
13.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | SARTORIUS AG |
Otto-Brenner-Straße 20 | |
37079 Göttingen | |
Germany | |
Phone: | +49.(0)551-308.0 |
Fax: | +49.(0)551-308.3289 |
E-mail: | info@sartorius.com |
Internet: | www.sartorius.com |
ISIN: | DE0007165607, DE0007165631 |
WKN: | 716560 , 716563 |
Indices: | DAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1901531 |
End of News | EQS News Service |
|
1901531 13.05.2024 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
Die wichtigsten Finanzdaten auf einen Blick | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Umsatzerlöse1 | 1.566,03 | 1.826,97 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.400,00 | |
EBITDA1,2 | 405,00 | 495,80 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 955,00 | |
EBITDA-Marge3 | 25,86 | 27,14 | 27,26 | 32,89 | 33,78 | 28,35 | 28,09 | |
EBIT1,4 | 298,61 | 335,66 | 456,11 | 903,16 | 1.070,00 | 503,90 | 530,00 | |
EBIT-Marge5 | 19,07 | 18,37 | 19,53 | 26,18 | 25,63 | 14,84 | 15,59 | |
Jahresüberschuss1 | 197,48 | 218,74 | 299,56 | 426,98 | 655,40 | 290,00 | 205,00 | |
Netto-Marge6 | 12,61 | 11,97 | 12,83 | 12,38 | 15,70 | 8,54 | 6,03 | |
Cashflow1,7 | 244,52 | 377,19 | 511,53 | 865,81 | 734,20 | 853,60 | 880,00 | |
Ergebnis je Aktie8 | 2,56 | 3,06 | 4,37 | 8,08 | 9,57 | 4,94 | 2,90 | |
Dividende8 | 0,61 | 0,35 | 0,70 | 1,25 | 1,43 | 0,73 | 0,73 |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: -
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
INVESTOR-INFORMATIONEN | ||||||
©boersengefluester.de | ||||||
Sartorius ST | ||||||
WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
716560 | DE0007165607 | AG | 14.676,48 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
KGV 2025e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
44,10 | 39,18 | 1,13 | 40,56 | 5,05 | 15,47 | 4,32 |
Dividende '2022 in € |
Dividende '2023 in € |
Dividende '2024e in € |
Div.-Rendite '2024e in % |
1,43 | 0,73 | 0,73 | 0,41% |
Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
27.03.2025 | 18.04.2024 | 19.07.2024 | 17.10.2024 | 16.02.2024 |
Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
-4,84% | -12,84% | -33,43% | -32,80% | +2.483,86% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.